Closing
Do GLP-1 receptor agonists improve neuropathy, eye & foot versus placebo?
Mostly studied in type 2 & unspecified diabetes.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 1
Already under way
- The SEMAFOOT2 Pilot Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes PatientsNCT07581145 · recruiting · started 2026
- Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2…NCT07723820 · not yet recruiting · started 2026
- Does the Preoperative Use of GLP-1 Agonists Change Outcomes in Patients Waiting for Total Hip and Knee Arthroplasty: A Pilot Randomized Control TrialNCT07755085 · not yet recruiting · started 2026
- Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) InitiationNCT07784127 · not yet recruiting · started 2026
- Effects of Combined Menopausal Hormone Therapy and GLP-1 Receptor Agonist Therapy on Glucose and Energy Homeostasis in Early Postmenopausal Women With or at…NCT06715514 · active not recruiting · started 2025
The evidence so far
- Registered trials
- 49
- With posted results
- 25
- Published papers
- 2
Of 9 decided analyses: 2 favor glp-1 receptor agonists, 7 find no difference, 0 favor the comparator.
Papers
- Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.Observational study · 2026
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.Observational study · 2025
Trials
- A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular EventsNCT01179048 · 9 posted results
- Clinical Study on the Improvement of Diabetic Neuropathic Pain by LiraglutideNCT04137328
- Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)NCT07723820
- A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 DiabetesNCT02692716 · 1 posted result
- Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.NCT02906930 · 1 posted result
- Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 DiabetesNCT02607865 · 1 posted result
- Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes MellitusNCT02863328 · 1 posted result
- Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes MellitusNCT02863419 · 1 posted result